Alemtuzumab
- Generic Name
- Alemtuzumab
- Brand Names
- Campath, Lemtrada, MabCampath
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216503-57-0
- Unique Ingredient Identifier
- 3A189DH42V
- Background
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...
- Indication
用于烷化剂氟达拉滨（fludarabine）治疗失败的B细胞性慢性淋巴细胞白血病患者；亦可用于复发缓解型多发性硬化症治疗。
- Associated Conditions
- B-Cell Chronic Lymphocytic Leukemia, Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Steroid Refractory Acute Graft Versus Host Disease, T-cell Prolymphocytic Leukemia (T-PLL), Refractory Autoimmune Hemolytic Anemia, Refractory Idiopathic thrombocytopenic purpura
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2017-09-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 28
- Registration Number
- NCT00935792
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)
- Conditions
- Interventions
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2011-10-06
- Lead Sponsor
- King Chulalongkorn Memorial Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT00930605
- Locations
- 🇹🇭
King Chulalongkorn Memorial Hospital, Bangkok, Thailand
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 6
- Registration Number
- NCT00923182
Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Conditions
- Interventions
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 3
- Registration Number
- NCT00881556
- Locations
- 🇺🇸
The Children's Hospital, Aurora, Colorado, United States
🇺🇸Morgan Stanley Children's Hospital of NYP, New York, New York, United States
🇺🇸Children's Memorial Hospital, Chicago, Illinois, United States
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
- Conditions
- Interventions
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 1
- Registration Number
- NCT00801931
- Locations
- 🇺🇸
Columbia Presbyterian Medical Center, New York, New York, United States
Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- CABYC
- Target Recruit Count
- 34
- Registration Number
- NCT00781781
- Locations
- 🇪🇸
Hospital Clinic i Provincial., Barcelona, Cataluña, Spain
🇪🇸Hospital Clinico de Valencia, Valencia, Comunidad Valenciana, Spain
🇪🇸Hospital Santa Creu i Sant Pau, Barcelona, Spain
Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants
- Conditions
- Interventions
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 78
- Registration Number
- NCT00775632
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
Alemtuzumab + Rituximab Consolidation in CLL
- Conditions
- Interventions
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00771602
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Autologous Stem Cell Transplantation for Crohn's Disease
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Paul Szabolcs
- Target Recruit Count
- 20
- Registration Number
- NCT00692939
- Locations
- 🇺🇸
UPMC Prebyterian- Adult Gastroenterology, Pittsburgh, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC-Bone Marrow Team, Pittsburgh, Pennsylvania, United States
Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)
- Conditions
- Interventions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 1
- Registration Number
- NCT00684255
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.